Antonell A, Gelpi E, Sanchez-Valle R, Martinez R, Molinuevo JL, Llado A (2012) Breakpoint sequence analysis of an AbetaPP locus duplication associated with autosomal dominant Alzheimer’s disease and severe cerebral amyloid angiopathy. J Alzheimers Dis 28:303–308. https://doi.org/10.3233/JAD-2011-110911

Article  CAS  PubMed  Google Scholar 

Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110:345–359. https://doi.org/10.1007/s00401-005-1074-9

Article  CAS  PubMed  Google Scholar 

Baksh RA, Pape SE, Chan LF, Aslam AA, Gulliford MC, Strydom A, Consortium G-D (2023) Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: a population-based cohort study using electronic health records. Lancet Public Health 8:e453–e462. https://doi.org/10.1016/S2468-2667(23)00057-9

Article  Google Scholar 

Bayer TA (2022) Pyroglutamate Abeta cascade as drug target in Alzheimer’s disease. Mol Psychiatry 27:1880–1885. https://doi.org/10.1038/s41380-021-01409-2

Article  CAS  PubMed  Google Scholar 

Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36:297–309. https://doi.org/10.1016/j.tips.2015.03.002

Article  CAS  PubMed  Google Scholar 

Blom ES, Viswanathan J, Kilander L, Helisalmi S, Soininen H, Lannfelt L et al (2008) Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer’s disease. Eur J Hum Genet 16:171–175. https://doi.org/10.1038/sj.ejhg.5201966

Article  CAS  PubMed  Google Scholar 

Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T et al (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005–1013. https://doi.org/10.1016/s0896-6273(00)80230-5

Article  CAS  PubMed  Google Scholar 

Brinkmalm G, Portelius E, Ohrfelt A, Mattsson N, Persson R, Gustavsson MK et al (2012) An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. J Mass Spectrom 47:591–603. https://doi.org/10.1002/jms.2987

Article  CAS  PubMed  Google Scholar 

Buss L, Fisher E, Hardy J, Nizetic D, Groet J, Pulford L et al (2016) Intracerebral haemorrhage in Down syndrome protected or predisposed? F1000Res. https://doi.org/10.12688/f1000research.7819.1

Article  PubMed  PubMed Central  Google Scholar 

Cabrejo L, Guyant-Marechal L, Laquerriere A, Vercelletto M, De la Fourniere F, Thomas-Anterion C et al (2006) Phenotype associated with APP duplication in five families. Brain 129:2966–2976. https://doi.org/10.1093/brain/awl237

Article  PubMed  Google Scholar 

Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernandez S, Videla L et al (2017) Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer’s disease. Alzheimers Dement 13:1251–1260. https://doi.org/10.1016/j.jalz.2017.03.007

Article  PubMed  Google Scholar 

Carmona-Iragui M, Videla L, Lleo A, Fortea J (2019) Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: the complex triangle of brain amyloidosis. Dev Neurobiol 79:716–737. https://doi.org/10.1002/dneu.22709

Article  PubMed  Google Scholar 

Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF et al (2022) The Boston Criteria Version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective MRI-neuropathology diagnostic accuracy study. Lancet Neurol 21:714–725. https://doi.org/10.1016/S1474-4422(22)00208-3

Article  PubMed  PubMed Central  Google Scholar 

Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K et al (2021) Comparing amyloid-beta plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathol 142:689–706. https://doi.org/10.1007/s00401-021-02342-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ et al (2022) Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol 21:140–152. https://doi.org/10.1016/S1474-4422(21)00375-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chowdhury SR, Xie F, Gu J, Fu L (2019) Small-molecule amyloid beta-aggregation inhibitors in Alzheimer’s disease drug development. Pharmaceutical Fronts 01:e22–e32. https://doi.org/10.1055/s-0039-1698405

Article  Google Scholar 

Crehan H, Liu B, Kleinschmidt M, Rahfeld JU, Le KX, Caldarone BJ et al (2020) Effector function of anti-pyroglutamate-3 abeta antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice. Alzheimers Res Ther 12:12. https://doi.org/10.1186/s13195-019-0579-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cullen N, Janelidze S, Palmqvist S, Stomrud E, Mattsson-Carlgren N, Hansson O et al (2022) Association of CSF Abeta(38) levels with risk of Alzheimer disease-related decline. Neurology 98:e958–e967. https://doi.org/10.1212/WNL.0000000000013228

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Kort AM, Kuiperij HB, Marques TM, Jakel L, van den Berg E, Kersten I et al (2023) Decreased Cerebrospinal Fluid amyloid beta 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. Ann Neurol 93:1173–1186. https://doi.org/10.1002/ana.26610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Fede G, Catania M, Maderna E, Ghidoni R, Benussi L, Tonoli E et al (2018) Molecular subtypes of Alzheimer’s disease. Sci Rep 8:3269. https://doi.org/10.1038/s41598-018-21641-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunys J, Valverde A, Checler F (2018) Are N- and C-terminally truncated Abeta species key pathological triggers in Alzheimer’s disease? J Biol Chem 293:15419–15428. https://doi.org/10.1074/jbc.R118.003999

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duyckaerts C, Delatour B, Potier MC (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118:5–36. https://doi.org/10.1007/s00401-009-0532-1

Article  CAS  PubMed  Google Scholar 

Gkanatsiou E, Nilsson J, Toomey CE, Vrillon A, Kvartsberg H, Portelius E et al (2021) Amyloid pathology and synaptic loss in pathological aging. J Neurochem 159:258–272. https://doi.org/10.1111/jnc.15487

Article  CAS  PubMed  Google Scholar 

Gkanatsiou E, Portelius E, Toomey CE, Blennow K, Zetterberg H, Lashley T et al (2019) A distinct brain beta amyloid signature in cerebral amyloid angiopathy compared to Alzheimer’s disease. Neurosci Lett 701:125–131. https://doi.org/10.1016/j.neulet.2019.02.033

Article  CAS  PubMed  Google Scholar 

Gkanatsiou E, Sahlin C, Portelius E, Johannesson M, Soderberg L, Falting J et al (2021) Characterization of monomeric and soluble aggregated Abeta in Down’s syndrome and Alzheimer’s disease brains. Neurosci Lett 754:135894. https://doi.org/10.1016/j.neulet.2021.135894

Article  CAS  PubMed  Google Scholar 

Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885–890. https://doi.org/10.1016/s0006-291x(84)80190-4

Article  CAS  PubMed  Google Scholar